Aurora Cannabis Urges Investors to Reject Curaleaf's Hostile Bid

August 24, 2026

Photo by websubs via Pixabay.

Boardroom disputes usually play out in filings and lawyers' letters. This one is playing out on social media too. Aurora Cannabis and Curaleaf, two of the largest cannabis companies on either side of the Atlantic, are now trading pointed public statements over a hostile takeover bid that Aurora's leadership wants shareholders to reject outright. Curaleaf calls it a premium offer for a company that has struggled with restructuring costs and writedowns for years. Aurora calls it an attempt to grab its European medical cannabis assets on the cheap before their value is fully reflected in the stock price.

What makes this more than the usual back-and-forth is the calendar. Canadian takeover rules impose a statutory minimum bid period, which means there's now a hard deadline forcing both sides to make their case to shareholders in public, on the record, and under time pressure. That's why the tone has gotten sharper than typical M&A chatter, and why shareholders are being asked to make a real decision rather than just watch from the sidelines.

How We Got Here: Timeline of the Bid

Photo by Pixabay via Pexels.

The bid didn't emerge out of nowhere. According to Aurora's account of the dialogue, Curaleaf first approached the company privately on June 23, 2026, opening a conversation that stayed behind closed doors for roughly seven weeks. That changed on August 11, 2026, when Curaleaf went public with its intent to bid, a move that put pressure on Aurora's board to respond in the open rather than negotiate quietly. The formal step came a week later: on August 18, 2026, Curaleaf filed its offer and take-over bid circular with the SEC, converting what had been an announced intention into a live, structured offer with defined terms and deadlines.

The strategic logic behind the deal is straightforward on paper. Curaleaf is largely a US multi-state operator with a growing European footprint, while Aurora has built out EU-GMP certified production and medical cannabis distribution across several European markets. If the acquisition closes, the combined company would operate in 17 countries spanning Europe, North America and other markets, giving Curaleaf a global medical cannabis platform far larger than what either company holds on its own.

That scale is exactly why the timeline matters so much right now. Canada's takeover bid regime requires a minimum bid period of 105 days from the date a bid is formally made, and that clock is now running. Barring an extension or amendment, the offer stays open until December 1, 2026. That's roughly three and a half months during which Aurora's board, its special committee, and Curaleaf will all be making their respective cases directly to shareholders, and during which competing offers or amended terms could still surface.

The Offer: What Aurora Shareholders Would Get

Photo by Pixabay via Pexels.

Strip away the back-and-forth statements and the offer itself has a fairly specific structure. Curaleaf is proposing total consideration of $4.00 per Aurora share, split between 0.3463 of a Curaleaf subordinate voting share and $0.75 in cash. That mix means Aurora shareholders wouldn't simply be cashed out; they'd end up holding a stake in the combined entity, with their financial outcome tied partly to how Curaleaf's stock performs after closing.

There's also a ceiling built into the structure. The offer is capped at a maximum value of $5.00 per Aurora share, and the exact number of Curaleaf shares issued gets adjusted if Curaleaf's own 20-day volume-weighted average price rises above C$17.05. In practice, that mechanism protects Curaleaf from having to hand over disproportionately more equity if its stock rallies during the bid period, while still giving Aurora shareholders some upside exposure below that threshold.

Curaleaf's framing of the price is where things get more contentious. The company describes the offer as a 45% premium to Aurora's unaffected 30-day volume-weighted average price of $2.75. Curaleaf goes further, arguing that if you exclude the cash sitting on Aurora's balance sheet from the comparison, the effective premium works out closer to 110% relative to that same unaffected share price. Those are the numbers Curaleaf wants shareholders focused on.

None of this closes automatically, either. The bid requires more than 50% of Aurora's outstanding shares to be deposited, a separate 66.67% approval threshold on a fully diluted basis, clearance from relevant regulators, and no material adverse change affecting Aurora in the interim. Each of those conditions gives Aurora's board leverage, and gives shareholders real reasons to wait for more information before tendering.

Aurora's Case for Rejecting the Bid

Photo by Pexels.

Aurora's leadership isn't disputing that Curaleaf sees value here, they're disputing what Curaleaf is actually valuing. CEO Miguel Martin has argued publicly that Curaleaf's real target is Aurora's EU-GMP certified facilities and its established medical cannabis platforms, and that the company wants those assets at the lowest price it can get away with rather than paying for what they're actually worth.

The numbers Aurora is leaning on to make that case are recent and, in the company's view, understate the story if you only look at headline financials. Aurora reported 17% year-over-year international net revenue growth in fiscal Q1 2027, alongside record global medical cannabis revenue and adjusted EBITDA for the full fiscal year 2026. The company also points to three consecutive years of positive adjusted EBITDA, a track record it says undercuts any narrative that it's a business in decline.

Geographically, Aurora highlights continued growth in Germany, its position as a market leader in Poland, and expansion into the UK through its Internode Pharma and HAP Pharma acquisitions. Germany in particular has become a point of direct disagreement: Curaleaf has flagged regulatory risk tied to changes affecting reimbursed medical cannabis, but Aurora counters that the reimbursement segment made up under 10% of its total German sales volume even before those rule changes took effect, meaning the exposure Curaleaf is describing is smaller than portrayed.

Behind the scenes, Aurora has assembled a substantial advisory team. A special committee of independent directors is being advised by Torys LLP, with Stikeman Elliott and Paul, Weiss also engaged, alongside financial advisors Fort Capital Partners and Kingsdale Advisors handling shareholder communications and strategy.

The Public Fight Gets Personal

Photo by Pexels.

This dispute stopped being purely procedural once both companies started posting directly to shareholders and the public. Curaleaf took to X to argue that Aurora's response doesn't change the underlying facts, pointing to billions of dollars in writedowns, years of restructuring, and what it characterizes as bloated costs at Aurora. Curaleaf CEO Boris Jordan has separately argued that Aurora faces significant headwinds in both Canada and Germany, framing the acquisition as a rescue for a company facing structural problems in its two largest markets.

Martin hasn't let those characterizations sit unanswered. He's accused Curaleaf of trying to grab Aurora's most valuable assets cheaply rather than putting forward what he considers a fair offer, essentially arguing that Curaleaf is using Aurora's past restructuring history as cover to justify an undervalued bid for a business that has since turned a corner.

There's a procedural clock running underneath all this rhetoric. Aurora's formal Directors' Circular response is due within 15 days of the bid's launch, putting the filing date around September 2, 2026. That document will carry far more legal and financial weight than any social media post from either side, since it's where Aurora's board is required to lay out its actual recommendation to shareholders along with the reasoning behind it.

Given how sharp the exchanges have already gotten less than a month into a 105-day bid period, there's little reason to expect things to cool off. If anything, the public statements so far suggest both companies view shareholder opinion as something to be actively shaped through the media, not just through formal filings, and that pattern seems likely to continue through the fall.

What Happens Next for Shareholders

Photo by Towfiqu barbhuiya via Unsplash.

For Aurora shareholders, the practical question is what to do between now and the offer's expiry. Unless extended or amended, the window runs until December 1, 2026, giving investors a defined stretch of time to weigh Curaleaf's cash-and-stock offer against Aurora's argument that the company's international medical cannabis business is worth meaningfully more than what's on the table.

Regulatory approval is not a formality here. With the combined company positioned to operate across 17 countries, closing this deal would require clearance in multiple jurisdictions, each with its own review process and timeline. That footprint alone introduces real uncertainty about whether, or when, this transaction could actually close even if shareholders vote to approve it.

Aurora's Directors' Circular will be the document that matters most in the near term. It's where the board is obligated to lay out its formal recommendation, along with the valuation methodology behind it, giving shareholders something more substantive than press statements to evaluate the offer against.

Contested takeovers like this one don't always end with the original bidder's initial terms intact. Competing offers, sweetened terms from Curaleaf, or a white-knight alternative bidder are all plausible developments over a bid period this long, and shareholders should factor that possibility into any decision about when, or whether, to tender their shares.

Cannabis M&A remains subject to different rules and different levels of regulatory scrutiny depending on the country involved, and that patchwork is only getting more complex as companies like Aurora and Curaleaf build genuinely global operations. Shareholders weighing this decision should consult their own financial and legal advisors rather than relying solely on either company's public statements.

Strip away the dueling press statements and social media jabs, and this fight will ultimately be decided by two documents: Curaleaf's formal offer terms and Aurora's Directors' Circular, due around September 2, 2026. That circular is where Aurora's board has to move past characterizations of Curaleaf's motives and actually publish its own valuation methodology, laying out in specific terms why it believes $4.00 to $5.00 per share undervalues the company's international medical cannabis business.

Public sparring is useful for understanding how each side wants to frame the narrative, but it isn't where the numbers that matter actually get published. Shareholders trying to decide whether to tender, hold, or wait for a better offer would do well to treat the September 2 filing as the real starting point for their analysis, not the accusations traded in the weeks before it.